Skip to content
Colorectal Cancer Clinical Trials

Washington

Colorectal cancer clinical trials in Washington

68 colorectal cancer studies are recruiting participants at sites in 31 cities across Washington as of November 16, 2026, according to ClinicalTrials.gov.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every Washington city with a recruiting study

Seattle (50), Edmonds (9), Issaquah (7), Vancouver (7), Silverdale (6), Spokane (6), Bellingham (5), Kennewick (5), Renton (5), Lacey (4), Longview (4), Sedro-Woolley (4), Tacoma (4), Walla Walla (4), Aberdeen (3), Bellevue (3), Centralia (3), Everett (3), Mount Vernon (3), Yakima (3), Kirkland (2), Olympia (2), Wenatchee (2), Bonney Lake (1), Bothell (1), Federal Way (1), Georgetown (1), Gig Harbor (1), Northwest (1), Port Townsend (1), Puyallup (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Recently updated studies in Washington

Basic details from each study's public record (the 12 most recently updated of 68). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Recruiting in
    Seattle
    Registry record
    NCT06324357 · updated
  2. Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Genmab
    Recruiting in
    Olympia
    Registry record
    NCT07775287 · updated
  3. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Recruiting in
    Seattle
    Registry record
    NCT07488676 · updated
  4. A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pliant Therapeutics, Inc.
    Recruiting in
    Edmonds
    Registry record
    NCT06270706 · updated
  5. A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Seattle
    Registry record
    NCT06997497 · updated
  6. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Recruiting in
    Seattle
    Registry record
    NCT07659795 · updated
  7. Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Solstice Oncology, Inc.
    Recruiting in
    Seattle
    Registry record
    NCT07808151 · updated
  8. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Recruiting in
    Seattle
    Registry record
    NCT07020221 · updated
  9. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Recruiting in
    Spokane
    Registry record
    NCT07503808 · updated
  10. The Vanguard Study: Testing a New Way to Screen for Cancer

    • No phase
    • Ages 45 to 75
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Tacoma
    Registry record
    NCT06995898 · updated
  11. Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Recruiting in
    Aberdeen · Bellingham · Centralia · and 13 more U.S. locations
    Registry record
    NCT07018869 · updated
  12. Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Recruiting in
    Spokane · Tacoma
    Registry record
    NCT07228832 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Washington on ClinicalTrials.gov.

Ask about studies in Washington

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call